Bibliography
- ICH S6, Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, July 1997. Available from: http://www.ich.org/cache/compo/276-254-1.html [Last accessed 31 March 2008]
- Bussiere JL, Gross MC, Ruppel JM, et al. 60-Day repeated dose study of an anti-IgE antibody in cynomolgus monkeys. Toxicology 1997;36:271
- Sweeney TD, Marian M, Ruppel J, Bussiere JL. Pulmonary delivery of anti-IgE: Rationale for topical delivery to the airway. In: Fick RB, Jardieu PM, editors, IgE and anti-IgE therapy in asthma and allergic disease. New York: Marcel Dekker, Inc.; 2001. p. 283-98
- Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans – clinical significance, assessment and prediction. Curr Trends Pharm Biotechnol 2002;3:349-60
- Korte R, Weinbauer GF. Towards new horizons in primate toxicology. Munster: Waxmann; 2000
- Korte R, Vogel F, Weinbauer GF. Primate models in pharmaceutical drug development. Munster: Waxmann; 2002
- Zuhlke U, Korte S, Niggermann B, et al. The common marmoset (Callithrix jacchus) as a model in biotechnology. In: Korte R, Vogel F, Weinbauer GF, editors, Primate models in pharmaceutical drug development. Munster: Waxmann; 2002. p. 119-25
- TNKase® (tenecteplase) Product Approval Information. Available from: http://www.fda.gov/cder/biologics/products/tenegen060200.htm [Last accessed 31 March 2008]
- Aranesp® (darbepoetin alfa) Product Approval Information. Available from: http://www.fda.gov/cder/biologics/products/darbamg091701.htm [Last accessed 31 March 2008]
- Ryan AM, Terrell TG. Biotechnology and its products. In: Haschek W, editors, Handbook of toxicologic pathology. 2nd edition. San Diego: Academic Press; 2002. p. 479
- Bussiere JL, Hardy LM, Hoberman AM, et al. Reproductive effects of chronic administration of murine interferon-gamma. Reprod Toxicol 1996;10:379-91
- Clarke J, Leach W, Pippig S, et al. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul Toxicol Pharmacol 2004;40:219-26
- Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 2000;19:226-8
- Bolon B, Galbreath E, Sargent L, Weiss J. Genetic engineering and molecular technology. In: Krinke G, editors, The laboratory rat. London: Academic Press; 2000. p. 603-34
- Bolon B, Galbreath EJ. Use of genetically engineered mice in drug discovery and development: wielding Occam's razor to prune the product portfolio. Int J Toxicol 2002;21:55-64
- Doetschman T. Interpretation of phenotype in genetically engineered mice. Lab Anim Sci 1999;49:137-43
- Bugelski PJ, Herzyk DJ, Rehm S, et al. Preclinical development of Keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum Exp Toxicol 2000;19:230-43
- Ganesh Suntharalingam G, Perry MR, Ward S, et al. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med 2006;355:1-11